Skip to content

A multi-centre clinical study of Qingyun formula combined with Chinese medicine digital management intervention for MAFLD

A multi-centre clinical study of Qingyun formula combined with Chinese medicine digital management intervention for MAFLD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091661
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-07-05
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolism-associated fatty liver disease

Interventions

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18-65 years, male or female; 2.Diagnosis of hepatic steatosis by imaging (including ultrasound, MRI or FibroScan) or liver histology; 3.Informed and signed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Combined with other liver diseases, such as drug-induced hepatitis, autoimmune liver disease, alcoholic liver disease, chronic hepatitis C, hepatomegaly, autoimmune liver disease and other liver diseases, and end-stage liver disease; 3. Combined with infectious diseases, such as viral hepatitis, tuberculosis, AIDS, etc.; 4. Excessive alcohol consumption; 5. Drugs such as tamoxifen, etamivir, methotrexate, sodium valproate, and glucocorticoids and other drugs; 6. Combined with other serious systemic diseases, such as coronary heart disease, heart failure, stroke, renal insufficiency, tumour, serious infections, etc.; 7. Major surgery or major stressful events in the past 2 months; 8. Weight fluctuation of more than 5% of one's own body weight in the past 3 months; 9. Taking drugs that cause liver injury in the past 3 months; 10. Taking drugs to treat steatohepatopathy or to correct metabolic disorders in the past 3 months. metabolic disorders.

Design outcomes

Primary

MeasureTime frame
MRI-PDFF;

Secondary

MeasureTime frame
Fatty Liver Index;Triglycerides;Total cholesterol;High density lipoprotein cholesterol (HDL);Low density lipoprotein cholesterol (LDL);Non high density lipoprotein cholesterol;Small and dense low-density lipoprotein cholesterol;Lipoproteins;Serum free fatty acids;Lipoprotein associated phospholipase A2;Apolipoprotein A;Apolipoprotein B;Alanine aminotransferase;Aspartate transaminase;Bilirubin value;body mass index;Waist;Relative changes in patient weight before and after treatment (%);Body fat;visceral fat mass;Traditional Chinese Medicine Syndrome Score;Tongue image parameters;Pulse diagnosis parameters;

Countries

China

Contacts

Public ContactYuqun Cai

Zhejiang Provincial People's Hospital

yuqun8792@163.com+86 150 8865 8792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026